The DESTINEX study reveals a revolutionary approach to early gastric cancer detection through a 17-microRNA signature. With an impressive diagnostic performance of 96.3% and 95.3% area under the curve (AUC) in training and validation cohorts, this method could significantly enhance screening practices. Notably, the 10-microRNA DESTINEX signature demonstrated a 96.8% AUC for identifying early-stage cases, offering a noninvasive alternative to traditional endoscopy, ultimately aiming to reduce mortality from delayed diagnoses.
Journal Article by Sui S, Xu C (…) Goel A et 10 al. in JAMA Surg